These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 4258181)

  • 1. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center.
    N Engl J Med; 1972 Mar; 286(10):505-7. PubMed ID: 4258181
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia.
    Jick H; Porter JB
    J Clin Pharmacol; 1981 Oct; 21(10):456-8. PubMed ID: 6458626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Skin eruption during combined treatment with ampicilin, amoxicilin and allopurinol].
    Rimon D; Maor N; Kitzes-Cohen R; Cohen L
    Harefuah; 1980 Feb; 98(3):121-3. PubMed ID: 6448779
    [No Abstract]   [Full Text] [Related]  

  • 4. Ampicillin rash and hyperuricemia.
    Murphy TF
    Ann Intern Med; 1979 Aug; 91(2):324. PubMed ID: 157097
    [No Abstract]   [Full Text] [Related]  

  • 5. Ampicillin rashes. Collaborative study.
    Arch Dermatol; 1973 Jan; 107(1):74-6. PubMed ID: 4264699
    [No Abstract]   [Full Text] [Related]  

  • 6. [Severity and incidence of skin reactions of intolerance to uric acid inhibitors in renal insufficiency].
    Branger B; Méry D; Mion C; Mirouze J
    Ann Med Interne (Paris); 1976 AUG-SEP; 127(8-9):596-9. PubMed ID: 137686
    [No Abstract]   [Full Text] [Related]  

  • 7. Ampicillin rashes.
    N Engl J Med; 1972 Jun; 286(22):1217-8. PubMed ID: 4259898
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of inpatients with adverse drug reactions to allopurinol.
    Khoo BP; Leow YH
    Singapore Med J; 2000 Apr; 41(4):156-60. PubMed ID: 11063179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug rash with ampicillin and other penicillins.
    Shapiro S; Siskind V; Slone D; Lewis GP; Jick H
    Lancet; 1969 Nov; 2(7628):969-72. PubMed ID: 4186974
    [No Abstract]   [Full Text] [Related]  

  • 11. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis.
    Renwick IG
    Br Med J (Clin Res Ed); 1985 Aug; 291(6493):485. PubMed ID: 3160433
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dermatologic complications of allopurinol treatment of gout].
    Thomas J
    Rein Foie; 1969-1970; 12():129-33. PubMed ID: 4253577
    [No Abstract]   [Full Text] [Related]  

  • 13. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 14. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rush desensitization to allopurynol.
    Nitti F; Fumagalli M; Incorvaia C
    Allergy; 2003 Jul; 58(7):690. PubMed ID: 12823143
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy reviews: pathogenesis and clinical management of hyperuricemia and gout.
    Mangini RJ
    Am J Hosp Pharm; 1979 Apr; 36(4):497-504. PubMed ID: 433935
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug eruptions induced by allopurinol associated with HLA-B*5801.
    Zeng M; Zhang M; Liu F; Yan W; Kong Q; Sang H
    Indian J Dermatol Venereol Leprol; 2015; 81(1):43-5. PubMed ID: 25566896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of decrease in hyperuricemia levels on joint, kidney and other symptoms in patients with gout].
    Kawenoki-Minc E
    Ter Arkh; 1987; 59(4):25-8. PubMed ID: 3589999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.